Please login to the form below

Not currently logged in
Email:
Password:

gene-editing

This page shows the latest gene-editing news and features for those working in and with pharma, biotech and healthcare.

Novartis gets breakthrough tag from FDA for sickle cell drug

Novartis gets breakthrough tag from FDA for sickle cell drug

Most of those costs stem from hospitalisation for VOCs. Arguably the biggest hope for patients with the disease is gene therapy, which could offer a one-shot cure, and the first ... Meanwhile, last week, the FDA also granted breakthrough status to a

Latest news

  • After December slump, what’s in store for biotech in 2019? After December slump, what’s in store for biotech in 2019?

    However, Renaissance thinks the outlook for 2019 remains uncertain, although there are plenty of biotechs eyeing listings in the coming year, with the list heavily populated by gene editing and gene

  • Horizon Discovery and C4X to harness CRISPR for new cancer drugs Horizon Discovery and C4X to harness CRISPR for new cancer drugs

    Cambridge-based Horizon has its own proprietary gene editing and gene modulation technologies. ... Recent advancements in the gene-editing tool, CRISPR-Cas9, has enabled systematic 'functional genomic' screening to identify novel synthetic lethal genes

  • Roche's O’Day swaps big pharma for big biotech Roche's O’Day swaps big pharma for big biotech

    with Sangamo to use its zinc finger gene-editing platform for drug discovery, and a $1.2bn deal to acquire Nimbus Therapeutics and its non-alcoholic steatohepatitis (NASH) candidate selonsertib.

  • AZ and CRUK launch Cambridge genomics centre AZ and CRUK launch Cambridge genomics centre

    The advantage of CRISPR (short for Clustered Regularly Interspace Short Palindromic Repeat) lies within the speed at which scientists can perform gene editing. ... Speeding up the identification of the gene or genes involved helps to isolate the most

  • Duchenne UK backs Evox dystrophin delivery project Duchenne UK backs Evox dystrophin delivery project

    as well as experimental gene therapies that try to deliver a working dystrophin gene that are in clinical trials and gene-editing approaches such as CRISP/Cas9 that attempt to correct ... existing antibodies primed to respond to the viruses used to

More from news
Approximately 2 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    That means gene products hitting that Glybera price of $1m are, for now at least, unlikely. ... CRISPR Therapeutics, one of the companies working with the exciting cutting-edge CRISPR/Cas9 gene editing technology, is looking to begin a phase I trial with

  • 30 Women Leaders in UK Healthcare (part 3) 30 Women Leaders in UK Healthcare (part 3)

    23. Dr Kathy Niakan, Developmental Biologist, The Francis Crick Institute. The last few years have seen a huge surge of interest in new gene editing tools that have enormous potential as ... The greatest excitement is reserved for CRISPR-Cas9 gene editing

  • Gene therapy Gene therapy

    the promise of gene therapy in the early nineties could not be remotely met. ... From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty transposases, CRISPR-Cas9 gene editing, ARCUS gene editing, nucleic acid vaccines,

  • Deal Watch March 2017 Deal Watch March 2017

    Editas Medicine has entered a strategic R&D alliance where Allergan has exclusive access to Editas’s CRISPR genome-editing programmes in ocular health, as well as options to license up ... 100. Editas. Allergan. R&D alliance. LCA10 and up to four other

  • Winning the war against cancer Winning the war against cancer

    areas such as the gene-editing CRISPR technology.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Eric Rhodes becomes CEO of ERS Genomics Eric Rhodes becomes CEO of ERS Genomics

    In these roles, Rhodes was responsible for commercialising the company's genome editing technologies as well as driving its research and development. ... Biosciences. Foy said: “With his deep understanding of the gene-editing landscape and extensive

  • Marc Becker joins CRISPR Therapeutics Marc Becker joins CRISPR Therapeutics

    He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Random42 Partner with MedCity for BioJapan 2018

    J. Leading UK health scientists, universities and national research institutions will provide insight into the UK life sciences sector, and their work in ageing, gene editing and artificial intelligence.

  • Training the next generation of biotech leaders

    Novel technologies, coupled with programmes designed to drive cell and gene research and development, are ushering in a new era of therapies. ... It’s such a disruptive advancement – it’s just incredible to think it has all been made feasible

  • Perspective on biotech

    The emerging technologies revolutionising the biotech industry – from immunotherapy breakthroughs to cutting-edge gene editing techniques.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics